Side-by-side · Research reference
MatrixylvsMT-1
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED9/39 cited
BFDA-ApprovedHUMAN-REVIEWED9/51 cited
Matrixyl
Cosmeceutical Pentapeptide · Topical Anti-Aging
Topical · Dermal · Twice Daily
MT-1
α-MSH Analogue · FDA-Approved
SQ Implant · 60-Day Release
01Mechanism of Action
Parameter
Matrixyl
MT-1
Primary target
Dermal fibroblastsPaccola 2025
Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010
Pathway
Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling
α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis
Downstream effect
Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025
Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010
Feedback intact?
—
Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production
Origin
Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022
Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026
Antibody development
—
—
02Dosage Protocols
Parameter
Matrixyl
MT-1
Formulation concentration
0.5–5% in topical vehicle
Common cosmeceutical range; higher concentrations in clinical formulations.
—
Application frequency
Twice daily (AM/PM)
Standard cosmeceutical protocol.
—
Duration
8–12 weeks minimum for visible effect
Collagen synthesis requires sustained application.
Seasonal use (spring–autumn typical)
Aligned with peak UV exposure months.
Vehicle
Serum, cream, or emulsion base
Lipophilic carriers enhance penetration.
—
Standard dose
—
16 mg subcutaneous implant
FDA-approved formulation (Scenesse).
Frequency
—
Every 60 days
Sustained release implant — no daily administration required.
Evidence basis
—
Phase 3 RCT / FDA-approved orphan drug
Indication
—
Erythropoietic protoporphyria (EPP)
Narrow FDA approval — not licensed for cosmetic tanning.
Route
—
Subcutaneous implant — upper arm or abdomen
Stability
—
Norleucine/D-Phe substitutions enhance peptidase resistance
Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).
04Side Effects & Safety
Parameter
Matrixyl
MT-1
Irritation
Mild erythema, pruritus in sensitive skin (rare)
—
Allergic reaction
Contact dermatitis (uncommon)
—
Systemic absorption
Negligible — topical application only
—
Nausea
—
Common (>10%) — mild, transient
Implant site reaction
—
Erythema, bruising, tenderness at insertion site
Hyperpigmentation
—
Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010Habbema 2017
Expected melanogenic response — complicates pigmented lesion surveillance.
Melanocytic changes
—
Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017
Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.
Headache
—
Occasional (MC1R-independent melanocortin effects)
Photosensitivity (paradoxical)
—
Rare phototoxic reactions despite melanin increase
Contamination risk (unregulated)
—
Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010Habbema 2017
Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.
Absolute Contraindications
Matrixyl
- ·Known hypersensitivity to palmitoyl peptides
MT-1
- ·Hypersensitivity to afamelanotide or excipients
- ·Hepatic impairment (no safety data)
- ·Renal impairment (no safety data)
Relative Contraindications
Matrixyl
- ·Active dermatitis or open wounds at application site
MT-1
- ·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
- ·Pregnancy/lactation (insufficient data)
- ·Photosensitive dermatoses (other than EPP)
05Administration Protocol
Parameter
Matrixyl
MT-1
1. Cleanse
Wash face with gentle cleanser. Pat dry.
Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.
2. Application
Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.
Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.
3. Timing
Twice daily — morning and evening. Apply before heavier creams or sunscreen.
Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.
4. Storage
Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.
New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.
5. Monitoring
—
Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.
06Stack Synergy
Matrixyl
+ GHK-Cu
Multi-pathwayMatrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.
- Matrixyl
- 0.5–5% topical serum · AM/PM
- GHK-Cu
- 1–2% topical serum · same application
- Frequency
- Twice daily
- Primary benefit
- Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity
MT-1
— no documented stacks